Ceramide Synthase 6 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis

Susanne Schiffmann, Nerea Ferreiros, Kerstin Birod, Max Eberle, Yannick Schreiber, Waltraud Pfeilschifter, Ulf Ziemann, Sandra Pierre, Klaus Scholich, Sabine Grösch and Gerd Geisslinger

J Immunol 2012; 188:5723-5733; Prepublished online 27 April 2012;
doi: 10.4049/jimmunol.1103109
http://www.jimmunol.org/content/188/11/5723

Supplementary Material

http://www.jimmunol.org/content/suppl/2012/04/27/jimmunol.1103109.DC1

References

This article cites 44 articles, 15 of which you can access for free at:
http://www.jimmunol.org/content/188/11/5723.full#ref-list-1

Subscription

Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Ceramide Synthase 6 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis

Susanne Schiffmann,* Nerea Ferreiros,* Kerstin Birod,* Max Eberle,* Yannick Schreiber,* Waltraud Pfeilschifter,† Ulf Ziemann,† Sandra Pierre,* Klaus Scholich,* Sabine Grösch,* and Gerd Geisslinger*

Ceramides are mediators of apoptosis and inflammatory processes. In an animal model of multiple sclerosis (MS), the experimental autoimmune encephalomyelitis (EAE) model, we observed a significant elevation of C_{16:0}-Cer in the lumbar spinal cord of EAE mice. This was caused by a transiently increased expression of ceramide synthase (CerS) 6 in monocytes/macrophages and astroglia. Notably, this corresponds to the clinical finding that C_{16:0}-Cer levels were increased 1.9-fold in cerebrospinal fluid of MS patients. NO and TNF-α secreted by IFN-γ–activated macrophages play an essential role in the development of MS. In murine peritoneal and mouse-derived RAW 264.7 macrophages, IFN-γ–mediated expression of inducible NO synthase (iNOS)/TNF-α and NO/TNF-α release depends on upregulation of CerS6/C_{16:0}-Cer. Downregulation of CerS6 by RNA interference or endogenous upregulation of C_{16:0}-Cer mediated by palmitic acid in RAW 264.7 macrophages led to a significant reduction or increase in NO/TNF-α release, respectively. EAE/IFN-γ knockout mice showed a significant delay in disease onset accompanied by a significantly less pronounced increase in CerS6/C_{16:0}-Cer, iNOS, and TNF-α compared with EAE/wild-type mice. Treatment of EAE mice with l-cycloserine prevented the increase in C_{16:0}-Cer and iNOS/TNF-α expression and caused a remission of the disease. In conclusion, CerS6 plays a critical role in the onset of MS, most likely by regulating NO and TNF-α synthesis. CerS6 may represent a new target for the inhibition of inflammatory processes promoting MS development.

Received for publication October 28, 2011. Accepted for publication March 28, 2012.

Abbreviations used in this article: AUC, area under the curve; CerS, ceramide synthase; DR5, death receptor 5; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; Iba1, ionized calcium-binding adapter molecule 1; iNOS, inducible NO synthase; KO, knockout; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MOG, myelin oligodendrocyte protein; MS, multiple sclerosis; PTX, pertussis toxin; siRNA, small interfering RNA; WT, wild-type.

Copyright © 2012 by The American Association of Immunologists, Inc. 0022-1767/12/$16.00

The online version of this article contains supplemental material.

*Pharmazentrum Frankfurt/Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit, Institut für Klinische Pharmakologie, Klinikum der Goethe-Universität Frankfurt, 60590 Frankfurt/Main, Germany; and †Department of Neurology, Goethe University, Theodor-Stern-Kai 7, 60528 Frankfurt/Main, Germany

Address correspondence and reprint requests to Dr. Susanne Schiffmann, Institute of Clinical Pharmacology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany. E-mail address: susanne.schiffmann@med.uni-frankfurt.de

Downloaded from http://www.jimmunol.org/ by guest on April 16, 2017
the clinical symptoms in EAE mice. Furthermore, Cer_6:Cer levels were increased 1.9-fold in the cerebrospinal fluid of MS patients. In cell culture experiments, we demonstrate that Cer_6:Cer plays a critical role in IFN-γ-induced iNOS/TFN-α expression and NO/TNF-α release. Accordingly, EAE/IFN-γ knockout (KO) mice showed a significant delay in disease onset accompanied by a less pronounced increase in CerS6/Cer_6:Cer, iNOS, and TFN-α compared with EAE/wild-type (WT) mice. Overall, this study reveals an important role for Cer_6:Cer in the inflammatory process and subsequently in the induction of EAE.

Materials and Methods

Cells and reagents

RAW 264.7 mouse macrophages (courtesy of Prof. J. Pfeilschifter, University of Frankfurt, Frankfurt, Germany) and peritoneal macrophages were cultured and incubated in RPMI 1640 medium containing 10% FCS and 1% penicillin/streptomycin. Cells were cultured at 37°C in an atmosphere containing 5% CO₂. 1-cycloserine, fumonisin B1, palmitic acid, and 60-mer-methylprednisolone were purchased from Sigma-Aldrich (Darmstadt, Germany). IFN-γ, TFN-α, and IL-1β were purchased from PeproTech (Hamburg, Germany). Small interfering RNAs (siRNAs) for CerS6 (s109529) were purchased from Ambion (Darmstadt, Germany). Sphin-go lipids were purchased either from Avanti Polar Lipids (Alabaster, AL) or Matreya LLC (Pleasant Gap, PA). EAE (EK-0115) and control (CK-0115) kits were purchased from Hooke Laboratories (Lawrence, MA).

Induction and evaluation of EAE

In all experiments, ethics guidelines for investigations in conscious animals were obeyed, and the experiments were approved by the local ethics committee for animal research. Eight- to ten-week-old female C57BL/6 or IFN-γ KO (C57BL/6 background) mice weighing 18–20 g were obtained from Harlan Laboratories (Horst, The Netherlands) or The Jackson Laboratory (Bar Harbor, ME). The procedure used for the induction of EAE was conducted as recommended by Hooke Laboratories. Briefly, EAE mice received a s.c. injection in the upper and lower back of encephalitogenic myelin oligodendrocyte protein (MOG)35–55 (200 μg) in CFA, and one week later, they received an s.c. injection once the mice had reached a score of 0.5. As controls, EAE and control mice were treated with vehicle (saline) daily i.p. injections of PTX. Because CFA alone also exerts inflammatory properties (12), two control groups were used. In one group (control group), mice received neither CFA/PTX nor MOG, and in the other group, CFA-treated mice were treated with CFA containing M. tuberculosis and twice daily i.p. injections of PTX. The mice were examined daily for development of disabilities. Most (90%) of the EAE mice developed clinical symptoms after 13 ± 2 d. Mice that developed no clinical symptoms were excluded. Clinical scores were defined as follows: 0, no signs; 0.5, limp tail; 1, limp tail and weakness of hind legs; 2, limp tail and paresis of hind legs; 3, limp tail and paralysis of hind legs.

Treatment study

Both EAE mice and CFA-treated mice received treatment with 1-cycloserin, which has been shown to inhibit sphingolipid synthesis in the CNS over a dose range of 25–100 mg/kg in mice (13). In our study, mice were treated with 75 mg/kg 1-cycloserin dissolved in saline by daily i.p. injection once the mice had reached a score of 0.5. As controls, EAE and CFA-treated mice received daily i.p. injections of vehicle (saline). Altogether, the study comprised four groups: EAE mice treated with 1-cycloserin or saline and CFA-treated mice treated with 1-cycloserin or saline.

Cerebrospinal fluid from patients

Cerebrospinal fluid from patients was collected at the Department of Neurology of Goethe University (Frankfurt/Main, Germany). All patients gave written informed consent prior to participation, and the protocol was approved by the local ethics committee. All samples were stored at −80°C. Cerebrospinal fluid samples were collected from 16 MS patients and 10 control patients who suffered from other neurologic diseases (Tables I, II).

Preparation of tissue for histology studies

Animals were killed with carbon dioxide inhalation and perfused transcardially with PBS (for mRNA, protein, and sphingolipid analysis) followed by 4% paraformaldehyde (for immunohistochemistry). Spinal cord (lumbar segments) was extracted and stored at −80°C for mRNA, protein, and sphingolipid analysis. The tissue for immunohistochemistry (spinal cord) was kept in 4% paraformaldehyde for 1 h, placed overnight in 30% sucrose, embedded in tissue freezing medium (Jung: Leica Microsystems GmbH, Nussloch, Germany), then quickly frozen on dry ice and stored at −80°C.

Immunohistochemistry

Fourteen-micrometer sections were permeabilized in PBS containing 0.1% Triton X-100 for 10 min, then blocked in PBS containing 3% BSA and 0.1% Triton X-100 for 30 min at room temperature. The sections were incubated with the primary Ab at 4°C overnight, followed by fluorescence-labeled Abs diluted 1:800 for 2 h in PBS containing 0.1% Triton X-100. The following Abs were used in the dilution indicated: anti-CerS6 (1:100), anti-ionized calcium-binding adapter molecule 1 (1:200), anti-glial fibrillar acidic protein (GFAP) (rabbit polyclonal) Ab was purchased from Sigma-Aldrich (Darmstadt, Germany), and glial fibrillar acidic protein (GAP) (rabbit polyclonal) Ab was purchased from Sigma-Aldrich (Darmstadt, Germany). The Ab against iNOS (rabbit polyclonal) was purchased from Becton Dickinson (Heidelberg, Germany).

Preparation of crude protein extracts

RAW 264.7 macrophages were seeded in 5-cm dishes at a density of 5 × 10⁵ cells/dish. Cells were treated with 10 ng/ml or 0.5 ng/ml IFN-γ, 5 ng/ml TNF-α, 1 ng/ml IL-1β, and 25 μM palmitic acid for the indicated time points. IFN-γ (10 ng/ml) treated RAW 264.7 macrophages were cotreated with 70 μM fumonisin B1, 500 μM 1-cycloserin, or 1 μM methylprednisolone for 16 h. Cells were preincubated with methylprednisolone and 1-cycloserin for 90 min or for 30 min with fumonisin B1. IFN-γ (0.5 ng/ml) treated RAW 264.7 macrophages were cotreated with 25 μM palmitic acid for 20 h. Vehicle-treated cells were used as controls. At the end of the incubation period, the crude extracts were prepared and used as described recently (14). Tissue samples from spinal cord were homogenized in Tris–CHAPS buffer (10 mM Tris–HCl–20 mM CHAPS, pH 7.4) supplemented with protease inhibitors. The homogenate was centrifuged, and the pellet (CerS6) (resuspended in Tris–CHAPS buffer) and the supernatants (iNOS) were collected and stored at −80°C. Protein concentrations were assessed using the Bradford method.

Western blot analysis

Immunoblotting was performed as described previously (14). In brief, 30 μg cell lysate proteins and 30 μg tissue homogenates were used. Membranes were analyzed on the Odyssey infrared scanner from LI-COR (Bad Homburg, Germany). The Abs used were diluted as follows: primary Ab raised against iNOS (1:200), CerS6 (1:100), and GAPDH (1:1000). The GAPDH Ab was purchased from Ambion (Darmstadt, Germany).

Real-time quantitative PCR

RAW 264.7 macrophages and lumbar spinal cord were analyzed for mRNA levels by quantitative PCR as previously described (15). The expression levels of CerS1–CerS6, TNF-α, IFN-γ, GAPDH, and iNOS were determined by TaqMan analysis using the SYBR Green Kit (ABgene Limited, Epsom, U.K.) with an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Austin, TX). Relative expression of ceramide synthase family genes, GAPDH, TNF-α, IFN-γ, and iNOS was determined using the comparative C_₇ method normalizing relative values to the expression level of 18S RNA (spinal cord samples) or GAPDH (macrophages) as housekeeping gene. The designed primer sets for ceramide synthases, iNOS, and IFN-γ were adopted from Laviad et al. (16), from Chiang et al. (17), and from Nath et al. (18), respectively. The sequence for the TNF-α primer set was designed as follows: forward 5’-TGACAAAGC- TGTAGCCACCG-3’, reverse 5’-GCCCTTGCTCCCTTAGAGAAACC-3’. Linearity of the assays was determined by serial dilutions of the templates for each primer set separately.

Siliencing of ceramide synthase with siRNA

RAW 264.7 macrophages were transfected with 150 pmol CerS6 siRNA or 100 pmol scrambled siRNA as control. siPort Amine (Ambion, Darmstadt, Germany) was used for transfection according to the manufacturer’s protocol and as described previously (15). Briefly, Opti-MEM medium was incubated with transfection reagent for 10 min at room temperature, then
added to the siRNA solution consisting of Opti-MEM medium and siRNA, followed by an incubation for 10 min at room temperature. RAW 264.7 macrophages (3.5 × 10^5) were incubated with siRNA transfection solution, and the process was repeated after 24 h. After 41 h, the transfected RAW 264.7 macrophages were either harvested for mRNA isolation (RNA Isolation Kit; Qiagen, Hilden, Germany) or treated with IFN-γ for 16 h and subjected to sphingolipid analysis and NO determination. The effectiveness of the siRNA knockdown was verified using quantitative PCR.

**Determination of sphingolipid concentrations**

The quantitation of sphingolipid in macrophages was achieved as previously published (19). Briefly, cells were seeded at a density of 0.5 × 10^5/cm^2 dish and incubated for 24 h. Subsequently, cells were treated with various substances. Cells were counted in a Neubauer chamber and stored at −80°C. The counted cell number was used to normalize the measured sphingolipid amounts to cell number. The lipids were extracted with methanol after addition of internal standards (C17:0-Cer). For the quantification of sphingolipid concentrations in tissue samples, ~20–100 mg of tissue was homogenized in PBS on ice. Aliquots (20 μl) of tissue suspension (0.02 mg/ml) were extracted in 600 μl chloroform/methanol (7:1) after the addition of the internal standard (C17:0-Cer) and 80 μl water. The suspension was vigorously vortexed at 25°C for 1 min and centrifuged for 5 min at 25°C and 14,000 rpm. The supernatants were collected, and the extraction step was repeated. The combined organic phases were dried under a stream of nitrogen and redissolved in 50 μl methanol for quantification. C14:0-Cer, C16:0-Cer, C18:0-Cer, C20:0-Cer, C24:1-Cer, and C24:0-Cer were determined. The C14:0-, C18:1-, and C24:1-Cer concentrations were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously (19, 20). For the quantification of sphingolipid concentrations in cerebrospinal fluid, a 50-μl sample was extracted in 600 μl chloroform/methanol (7:1) after the addition of the internal standard (C17:0-Cer). Concentrations of the calibration standards, quality controls, and unknowns were evaluated using the Analyst software version 1.5 (Applied Biosystems). Linearity of the calibration curve was confirmed for C16:0-Cer from 0.3 to 500 ng/ml, for C18:0-Cer from 3 to 5000 ng/ml, for C18:0-Cer from 0.9 to 1500 ng/ml, and for C22:0-Cer from 1.2 to 2000 ng/ml. The coefficient of correlation for all measured concentrations was at least 0.99. Variations in accuracy and intra- and interday precision (n = 2 for each concentration in mouse tissue and cells) were <15% over the range of calibration.

**Determination of IFN-γ, TNF-α, and nitrite/nitrate**

RAW 264.7 macrophages and primary peritoneal macrophages were treated with various substances for the time points indicated. The cells were harvested and counted using the Neubauer chamber. The counted cell number was used for normalization of the measured products (TNF-α/NO). The supernatant was harvested, centrifuged (1200 rpm, 3 min, 4°C) and stored at −80°C. The release of NO was assessed by measuring concentrations of nitrite and nitrate in the supernatant (1 ml) using the Griess reagent. Amounts of NO were expressed as nanomoles per milligram of tissue C16:0-Cer, and 19.06 ± 8.91 μmol/mg tissue C16:0-Cer. The lumbar spinal cord revealed a significant increase in C16:0-Cer at the onset (sc=0.5–sc=1.5) of the disease, which persisted through the acute phase (sc=2–sc=3) of the disease (Fig. 1B). All other ceramide levels were unaltered in these mice. CFA-treated mice showed no changes in ceramide levels (Fig. 1B). Given these results in the EAE model of MS, we were interested whether C16:0-Cer levels are also upregulated in MS patients. Therefore, ceramide levels were measured by LC-MS/MS in the cerebrospinal fluid of MS patients and control patients not suffering from MS (Tables I, II). In the cerebrospinal fluid of MS patients (n = 16), the C16:0-Cer levels were significantly upregulated (1.9-fold) compared with those of control patients (n = 10) (Fig. 1C), strongly suggesting that C16:0-Cer may play a role in the development of MS.

**Preparation of peritoneal macrophages**

Eight- to ten-week-old female C57BL/6 mice (Harlan Laboratories, Horst, The Netherlands) received 0.5 ml of 10% thioglycollate (Sigma, St. Louis, MO) i.p. After 4 d, the mice were killed by inhalation with carbon dioxide. Peritoneal macrophages were collected by removing the skin from the abdomen and injecting 2 ml of lavage fluid (HBBS) and 2 ml air into the peritoneal cavity. The lavage fluid (enriched with macrophages) was collected from the peritoneal cavity using a 2-ml syringe. The step was repeated with 2 ml HBBS. Macrophages depleted of erythrocytes were cultured in RPMI 1640 medium containing 10% FCS and 1% penicillin/streptomycin. After 3 h, the cell medium was replaced, and the cells were used for further experiments. Peritoneal macrophages were incubated with 20 ng/ml IFN-γ for various time points. Peritoneal macrophages were costimulated with IFN-γ (20 ng/ml) and fumonisin B1 (70 μM) and L-cycloserine (500 μM) for 16 h. Cells were preincubated with fumonisin B1 and L-cycloserine for 30 min and 90 min, respectively.

**Statistics**

Results are presented as means ± SEM. Cell culture data and animal data were analyzed using one-way ANOVA. Significant differences were analyzed by the Bonferroni post hoc test (PASS Statistics 18 software). The clinical score data from t-cycloseline and saline-treated EAE mice were analyzed by calculating the area under the curve (AUC). The AUC values were analyzed using the t test. The level of significance was set at p < 0.05.

**Results**

C16:0-Cer levels are increased at the onset of EAE

Because ceramides play a supportive role in inflammatory processes, we hypothesized that ceramides are modified during the development of MS. To assess this hypothesis, we used the chronic EAE model in mice as an animal model for MS. After 13 ± 2 d, the mice started to develop the first signs of reduced motor skills, which deteriorated within 4 ± 1 d to complete paralysis of the hind paws (Fig. 1A). The cerebellar levels in the lumbar spinal cord were determined in CFA-treated (only treated with CFA-emulsion and PTX) and EAE mice using LC-MS/MS. The EAE mice were divided into two groups based on scores: sc=0.5–sc=1.5 (onset of the disease) and sc=2–sc=3 (acute phase of the disease). The concentrations of C14:0-Cer, C16:0-Cer, C18:0-Cer, C20:0-Cer, C18:1-Cer, C24:1-Cer, and C24:0-Cer were determined. The C14:0-, C18:1-, and C24:1-Cer levels were below the detection limit of 0.096 ng/ml (data not shown). The cerebellar concentrations in untreated mice were 0.47 ± 0.13 μmol/mg tissue C16:0-Cer, 10.05 ± 3.76 μmol/mg tissue C16:0-Cer, 14.41 ± 6.44 μmol/mg tissue C24:0-Cer, and 19.06 ± 8.91 μmol/mg tissue C24:0-Cer. The lumbar spinal cord revealed a significant increase in C16:0-Cer at the onset (sc=0.5–sc=1.5) of the disease, which persisted through the acute phase (sc=2–sc=3) of the disease (Fig. 1B). Other cerebrospinal fluid markers were unaltered in these mice. CFA-treated mice showed no changes in cerebellum levels (Fig. 1B).

C16:0-Cer levels are increased in the cerebrospinal fluid of MS patients

Next, we studied the extent to which the raised C16:0-Cer levels in EAE mice are due to increased expression of a specific ceramide synthase. For this purpose, mRNA levels of all ceramide synthases—apart from CerS3, which was not detectable—were determined in the lumbar spinal cord of CFA-treated and EAE mice (sc=0.5, sc=1.5, sc=3). Quantitative PCR revealed that the mRNA expression of CerS6 was significantly increased in mice at the onset of EAE (Fig. 1D). The mRNA data were confirmed at the protein level by Western blot analysis. The expression of CerS6 protein in homogenates of the lumbar spinal cord of untreated, CFA-treated, and EAE mice (sc=0.5, sc=1.5, sc=3) was determined. Sc=1.5 mice showed a significant increase in CerS6 compared with that of CFA-treated mice, whereas in sc=3 mice, CerS6 expression was reduced to the level of that of CFA-treated mice (Fig. 1F). Thus, the mRNA and protein expression profiles suggested a transient increase in CerS6 and C16:0-Cer during development of EAE.

CerS6 is expressed in inflammatory cells and in astroglia in EAE mice

Next, we assessed which cells are responsible for the increase in CerS6 and C16:0-Cer levels. Immunohistochemical analysis
of the lumbar spinal cord of untreated and EAE mice showed that CerS6 was expressed in oligodendrocytes (Supplemental Fig. 1A, data shown for untreated mice). In EAE mice (sc1.5), CerS6 was additionally expressed in the lesion site in the white matter of the lumbar spinal cord (Fig. 2A). CerS6 was expressed in macrophages as shown by colocalization of CerS6 and F4/80 (macrophage marker) (Fig. 2B). Furthermore, Ajami et al. (22) have shown recently that the lesion site of EAE mice con-

Table I. Demographic data of MS patients

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Sex</th>
<th>Age (y)</th>
<th>MS Type</th>
<th>EDSS</th>
<th>Duration (mo)</th>
<th>Treatment</th>
<th>Number of T2 Lesions</th>
<th>Cerebrospinal Fluid Leukocytes (cells/μl)/Protein (mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>31</td>
<td>RRMS</td>
<td>1.5</td>
<td>40</td>
<td>None</td>
<td>&gt;9</td>
<td>4/584</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>32</td>
<td>CIS</td>
<td>1.0</td>
<td>&lt;1</td>
<td>None</td>
<td>4</td>
<td>27/400</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>44</td>
<td>RRMS</td>
<td>2.5</td>
<td>120</td>
<td>None</td>
<td>&gt;9</td>
<td>0/556</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>41</td>
<td>SPMS</td>
<td>5.5</td>
<td>12</td>
<td>None</td>
<td>&gt;9</td>
<td>1/640</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>29</td>
<td>CIS</td>
<td>0</td>
<td>&lt;1</td>
<td>None</td>
<td>0</td>
<td>0/248</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>30</td>
<td>CIS</td>
<td>0</td>
<td>&lt;1</td>
<td>None</td>
<td>4</td>
<td>12/310</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>30</td>
<td>RRMS</td>
<td>3.5</td>
<td>48</td>
<td>None</td>
<td>&gt;9</td>
<td>9/414</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>45</td>
<td>SPMS</td>
<td>2.5</td>
<td>24</td>
<td>None</td>
<td>&gt;9</td>
<td>5/410</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>60</td>
<td>CIS</td>
<td>1.0</td>
<td>2</td>
<td>None</td>
<td>4</td>
<td>5/704</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>42</td>
<td>CIS</td>
<td>2.0</td>
<td>&lt;1</td>
<td>None</td>
<td>&gt;9</td>
<td>1/336</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>44</td>
<td>SPMS</td>
<td>2.0</td>
<td>18</td>
<td>None</td>
<td>&gt;9</td>
<td>2/485</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>55</td>
<td>CIS</td>
<td>3.0</td>
<td>3</td>
<td>None</td>
<td>4</td>
<td>10/303</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>29</td>
<td>CIS</td>
<td>3.0</td>
<td>2</td>
<td>None</td>
<td>1</td>
<td>1/219</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>27</td>
<td>RRMS</td>
<td>2</td>
<td>10</td>
<td>None</td>
<td>6</td>
<td>6/298</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>58</td>
<td>CIS</td>
<td>1</td>
<td>2</td>
<td>None</td>
<td>5</td>
<td>9/508</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>33</td>
<td>CIS</td>
<td>0</td>
<td>2</td>
<td>None</td>
<td>&gt;9</td>
<td>15/270</td>
</tr>
</tbody>
</table>

CIS, Clinically isolated syndrome; EDSS, Expanded Disability Status Scale; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
sists of infiltrating monocytes (CD11b positive), which differentiate to macrophages (CD11b positive, Iba1 positive) during the progress of the disease. Therefore, we investigated whether CerS6 is localized in these cell types. CerS6 was expressed in CD11b-positive and Iba1-positive cells (Iba1, CD11b, CerS6 triple staining) (Fig. 2C). These results pointed strongly to expression of CerS6 in macrophages, but it could not be excluded that microgla cells also express CerS6 because CD11b and Iba1 also stain microgla. CerS6 is also expressed in astroglia (GFAP staining) (Supplemental Fig. 1B). Because C16:0-Cer is considered to be involved in apoptotic processes, we investigated whether CerS6 is detectable in apoptotic cells. CerS6 was not expressed in DR5-positive cells (Supplemental Fig. 1C).

IFN-γ induces an increase in ceramides in macrophages

Next, we sought to investigate whether C16:0-Cer plays a role in the induction of EAE. Recent studies have revealed an important role of the Th1-mediated response in the development of EAE (23). Th1 cells secrete predominantly IFN-γ, IL-1β, and TNF-α, which in turn activate macrophages. Because CerS6 was expressed in macrophages, we used RAW 264.7 macrophages as a cell culture system. We studied the influence of IFN-γ, IL-1β, and TNF-α on

Table II. Demographic data of control patients

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Specification of Other Neurologic Disease</th>
<th>Cerebrospinal Fluid Leukocytes (cells/μl)/protein (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>44</td>
<td>Leukemia with monoclonal gammapathy (IgA) polyneuropathy</td>
<td>0/556</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>41</td>
<td>HIV CDC3, paraparesis without evidence of CNS lesion</td>
<td>1/375</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>54</td>
<td>Somatoform disorder</td>
<td>0/407</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>65</td>
<td>Vascular dementia</td>
<td>0/340</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>23</td>
<td>Somatoform disorder</td>
<td>0/181</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>40</td>
<td>Non-specific vertigo</td>
<td>0/139</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>40</td>
<td>Idiopathic intracranial hypertension</td>
<td>0/209</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>40</td>
<td>Frontotemporal dementia</td>
<td>0/310</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>50</td>
<td>Guillain-Barre syndrome</td>
<td>0/189</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>33</td>
<td>Nonspecific headache</td>
<td>1/215</td>
</tr>
</tbody>
</table>

FIGURE 2. CerS6 is selectively elevated at the onset of the disease in inflammatory cells. (A) Expression of CerS6 (red channel) in the lesion site in the white matter of the ventral horn (lumbar spinal cord) of sc1.5 EAE mice at two magnifications as indicated. (B and C) Expression of CerS6 (red channel) in macrophages in the lumbar spinal cord of sc1.5 EAE mice. (B) Staining with F4/80 (green) illustrates macrophages, and staining with DAPI illustrates the cell nucleus. Merge = overlay of CerS6 (red channel), F4/80 (green channel), and DAPI (blue channel). (C) Costaining of CerS6 (red), CD11b (green), and Iba1 (blue) in the lumbar spinal cord of sc1.5 EAE mice. Merge = overlay of CerS6 (red channel) and cell type-specific proteins (CD11b, green channel; Iba1, blue channel). All data are representative images of three independent experiments. Scale bar, 10 μm (A, original magnification ×5; scale bar, 25 μM (A, original magnification ×20). (D–H) The IFN-γ, iNOS, and TNF-α expression in EAE and CFA-treated mice. The relative mRNA levels (D) and protein levels of IFN-γ (E), mRNA expression levels of TNF-α (F), and mRNA levels (G) and protein levels (H) of iNOS from EAE and CFA-treated mice. The relative mRNA expression levels of IFN-γ, iNOS, and TNF-α were normalized to 18S RNA and were calculated using the mRNA levels of untreated mice of the same age as those at basal level. Data are means ± SEM of number of mice as indicated, and each measurement was made in triplicate.*p < 0.05, **p < 0.01, ***p < 0.001 (significant differences between EAE and untreated mice).
the ceramide levels in RAW 264.7 macrophages. Only IFN-γ induced in RAW 264.7 macrophages a significant elevation of C_{16:0}-Cer after 16-h treatment (Supplemental Fig. 1D). IFN-γ led to a time-dependent marked increase in C_{14:0}-Cer and C_{16:0}-Cer and to a slight increase in C_{24:0}-Cer (Fig. 3A). The fact that dihydroceramides were elevated (data not shown) indicated an activation of sphingolipid de novo synthesis. The mRNA levels of the various ceramide synthases in IFN-γ-treated RAW 264.7 macrophages supported the LC-MS/MS data and revealed a significant increase in the mRNA levels of CerS6 (Supplemental Fig. 1E). The mRNA expression of CerS6 in RAW 264.7 macrophages was transiently increased as in the lumbar spinal cord of EAE mice (Fig. 1D). The protein expression of CerS6 was also time-dependently elevated in IFN-γ-treated RAW 264.7 macrophages with a significant increase already after 6 h (Fig. 3B). The transient increase in CerS6 in the lumbar spinal cord, as well as in IFN-γ-treated RAW 264.7 macrophages, and the subsequent marked increase in C_{16:0}-Cer in both experimental setups indicated that the in vitro experiment simulates very closely the in vivo situation.

FIGURE 3. C_{16:0}-Cer mediates IFN-γ–induced NO release in RAW 264.7 macrophages. (A and B) The time-dependent effect of IFN-γ–treated RAW 264.7 macrophages on ceramide levels (A) and on the expression of CerS6 (B). RAW 264.7 macrophages were treated at the time points indicated with IFN-γ (10 ng/ml) or were left untreated. (A) The ceramide levels were normalized to the number of treated cells. The relative increase in specific ceramides was calculated taking the ceramide levels of untreated cells as 100%. (B) Densitometric and Western blot analysis of CerS6 expression. CerS6 expression was related to the expression level of GAPDH, which was used as loading control. One representative blot of three is shown. Data are means ± SEM of three independent experiments. (C) Protein expression, expression of iNOS mRNA, and NO release were increased in a time-dependent manner in IFN-γ (10 ng/ml) treated RAW 264.7 macrophages. For Western blot analysis, GAPDH was used as the loading control (one of two independent experiments is shown). The amount of NO was determined in the supernatant and normalized to the number of cells. The relative expression of iNOS mRNA was normalized to GAPDH and was calculated using the mRNA level of untreated cells as the basal level. (D and E) Fumonisin B1 (FB1; 70 μM), L-cycloserine (Cyclo; 500 μM), and methylprednisolone (MP; 1 μM) prevent the IFN-γ (10 ng/ml) induced increase in NO synthesis in RAW 264.7 macrophages. After IFN-γ incubation (16 h), NO release (D) and the level of iNOS mRNA (E) were measured in RAW 264.7 macrophages. For normalization, the amount of NO was related to the number of treated cells. The relative expression of iNOS mRNA was normalized to GAPDH and was calculated using untreated cells at the same time point as the basal level. Data are means ± SEM of three independent experiments, each carried out in duplicate. *p < 0.05, **p < 0.01, ***p < 0.001 (significant differences between IFN-γ–treated and untreated RAW 264.7 macrophages).
inhibitors of sphingolipid synthesis. l-Cycloserine (an inhibitor of serine palmitoyltransferase) and fumonisin B1 (a nonselective inhibitor of ceramide synthases) prevented the increase in ceramides induced by IFN-γ in RAW 264.7 macrophages (Supplemental Fig. 2A). The inhibition by l-cycloserine of IFN-γ-induced ceramide synthesis indicates that IFN-γ induces de novo synthesis rather than the salvage pathway of ceramide synthesis. Importantly, l-cycloserine and fumonisin B1 were as effective in inhibiting IFN-γ-induced NO release as the anti-inflammatory glucocorticoid methylprednisolone (Fig. 3D). Additionally, l-cycloserine and FB1 prevented the IFN-γ-induced upregulation of the mRNA expression of iNOS (Fig. 3E), thus ruling out nonselective inhibition of the activity of iNOS. Neither fumonisin B1 nor l-cycloserine reduced cell viability in IFN-γ-pretreated macrophages (Supplemental Fig. 2B). The temporal relationship between CerS6 and iNOS expression and the fact that inhibition of ceramide synthesis prevented IFN-γ-induced NO release suggest that CerS6 acts upstream of iNOS.

To verify that predominantly C₁₆:₀-Cer and CerS6 mediate the NO increase in IFN-γ-treated macrophages, CerS6 was downregulated with RNA interference technology. siCerS6-pretreated RAW 264.7 macrophages were stimulated with 10 ng/ml IFN-γ for 16 h. CerS5, which has a similar substrate specificity to that of CerS6, was not regulated by siCerS6 (Supplemental Fig. 2C). siCerS6 prevented IFN-γ-induced CerS6 upregulation, whereas scrambled siRNA had no effect (Supplemental Fig. 2C). The downregulation of CerS6 selectively prevented the increase in C₁₆:₀-Cer (data not shown) and C₁₆:₀-Cer (Supplemental Fig. 2D), but not that in C₂₄:₀-Cer (data not shown), which was also slightly upregulated in IFN-γ-treated cells (Fig. 3A). As expected, siCerS6 prevented IFN-γ-induced iNOS mRNA expression and TNF-α mRNA expression and TNF-α release were also inhibited by fumonisin B1 and l-cycloserine (Fig. 4E, 4F). As expected, siCerS6 prevented IFN-γ-induced TNF-α mRNA expression (Fig. 4G) and TNF-α release (Fig. 4H) in RAW 264.7 macrophages compared with scrambled siRNA-treated RAW 264.7 macrophages. Moreover, exogenously added palmitic acid (25 μM) amplified the IFN-γ (0.5 ng/ml) induced TNF-α synthesis in RAW 264.7 macrophages (Fig. 4F).

C₁₆:₀-Cer mediate IFN-γ-induced TNF-α release in RAW macrophages

Because TNF-α, like NO, is a mediator of inflammatory processes, we investigated whether TNF-α is also regulated by C₁₆:₀-Cer. As postulated, TNF-α was upregulated in EAE mice in a disease-dependent manner (Fig. 2F). IFN-γ induced the expression of TNF-α mRNA in macrophages, which could be inhibited by methylprednisolone (1 μM) (Fig. 4E). IFN-γ-induced TNF-α mRNA expression and TNF-α release were also inhibited by fumonisin B1 and l-cycloserine (Fig. 4E, 4F). As expected, siCerS6 prevented IFN-γ-induced TNF-α mRNA expression (Fig. 4G) and TNF-α release (Fig. 4H) in RAW 264.7 macrophages compared with scrambled siRNA-treated RAW 264.7 macrophages. Moreover, exogenously added palmitic acid (25 μM) amplified the IFN-γ (0.5 ng/ml) induced TNF-α synthesis in RAW 264.7 macrophages (Fig. 4F).
C_{16:0}-Cer mediates IFN-γ–induced TNF-α and NO release in peritoneal macrophages

In peritoneal macrophages, we investigated whether NO and TNF-α release are dependent on C_{16:0}-Cer. In peritoneal macrophages, IFN-γ induced a time-dependent, transient increase in CerS6, which resulted in a significant increase in C_{16:0}-Cer after 16 h (Fig. 5A, 5B). Notably, the IFN-γ–induced release of NO and TNF-α could be inhibited by fumonisin B1 as well as by l-cycloserine (Fig. 5C, 5D). These data indicate that in primary macrophages, the synthesis of NO and TNF-α is also C_{16:0}-Cer dependent.

C_{16:0}-Cer concentrations and iNOS, TNF-α, and CerS6 expression are reduced during the initial phase of disease in IFN-γ KO EAE mice

Next, we were interested in whether IFN-γ is relevant for the elevated C_{16:0}-Cer/CerS6 levels in the EAE model. For this purpose, we induced EAE in IFN-γ KO mice. We observed a significant delay in disease onset, as described by Pál et al. (27). EAE/IFN-γ KO mice developed initial signs of clinical symptoms at day 12 ± 1 and EAE/WT mice at day 10 ± 1. Ceramide levels and mRNA expression were determined in EAE/WT and EAE/IFN-γ KO mice, when sc0.5 was reached. Notably, the expression of mRNAs for CerS6, iNOS, and TNF-α were significantly reduced in EAE/IFN-γ KO mice when compared with EAE/WT mice (Fig. 5E). Furthermore, in EAE/IFN-γ KO mice, the C_{16:0}-Cer level was significantly lower compared with that of EAE/WT mice (Fig. 5F). Most importantly, CerS6 and iNOS protein was also clearly lower in EAE/IFN-γ KO mice than in EAE/WT mice (Fig. 5G). The reduced CerS6 and iNOS expression in EAE/IFN-γ KO mice confirms our in vitro results showing that IFN-γ induces the synthesis of CerS6/C_{16:0}-Cer, which subsequently is relevant for the induction of iNOS.

Inhibition of C_{16:0}-Cer prevents worsening of the clinical symptoms in the EAE model

NO and TNF-α production were related to tissue-damaging effects and the initiation of a myelin-directed immune response, respectively, during the onset and in the acute phase of the EAE model (2, 3). Because C_{16:0}-Cer was linked to NO and TNF-α release in peritoneal macrophages, we studied the effects of inhibition of ceramide synthesis in EAE mice by l-cycloserine, given at the onset of the disease. Mice were treated with 75 mg/kg l-cycloserine (i.p.) once daily starting when the mice showed the first signs of clinical symptoms (sc0.5). The control EAE mice were treated with vehicle. The AUC for clinical score in l-cycloserine–treated EAE mice was 10.51 ± 1.8 score units/day and that in vehicle-treated EAE mice was 17.69 ± 2.3 score units/day. Treatment with l-cycloserine significantly prevented (p = 0.041) the development of clinical symptoms (Fig. 6A). Fig. 6B reveals

![Figure 5](http://www.jimmunol.org/)

**FIGURE 5.** C_{16:0}-Cer mediates IFN-γ–induced NO and TNF-α release from peritoneal macrophages. (A) Time-dependent effect of IFN-γ–treated peritoneal macrophages on the expression of CerS6 mRNA. Peritoneal macrophages were treated or not with IFN-γ (20 ng/ml) for the time points indicated. The relative expression of CerS6 mRNA was normalized to GAPDH and was calculated using untreated cells at the same time point as basal level. Data are means ± SEM of two independent experiments, each performed in duplicate. **p < 0.01 (significant difference between IFN-γ–stimulated and unstimulated peritoneal macrophages). (B–D) Fumonisin B1 (FB1; 70 μM) and l-cycloserine (Cyclo; 500 μM) prevented the IFN-γ (20 ng/ml) induced increase in NO and TNF-α synthesis in peritoneal macrophages. The amount of C_{16:0}-Cer (B) and release of NO (C) and TNF-α (D) were measured in peritoneal macrophages (after 16 h). The relative expression of CerS6 mRNA was normalized to GAPDH. Ceramide, NO, and TNF-α levels were normalized to the number of treated cells. Ceramide levels of untreated cells were set at 100%. Data are means ± SEM of three independent experiments each performed in duplicate. **p < 0.01, ***p < 0.001 (significant differences between IFN-γ stimulated and IFN-γ/specific inhibitor costimulated peritoneal macrophages). (E–G) EAE experiment using IFN-γ KO mice. IFN-γ KO or WT mice were immunized on day 0 with MOG35–55 peptide dissolved in CFA and received PTX on day 0 and day 1. CFA-treated mice received an injection of CFA only. The results were obtained from a single study. (E) The relative expression of mRNA for CerS6, IFN-γ, TNF-α, and iNOS from EAE/IFN-γ KO and EAE/WT mice at the onset of the disease (sc0.5) was calculated using the mRNA levels of untreated mice of the same age as those at baseline. Data are means ± SEM of number of mice as indicated; each measurement was done in triplicate. **p < 0.05, ***p < 0.01, ****p < 0.001 (significant differences between EAE/IFN-γ KO and EAE/WT mice). (F and G) C_{16:0}-Cer (F), CerS6 (G), and iNOS (G) expression in the lumbar spinal cord of EAE/IFN-γ KO and EAE/WT at the onset of the disease (sc0.5). The ceramide levels of untreated mice were set at 100%. (G) Western blots from one EAE/WT (sc0.5) and two EAE/IFN-γ KO (sc0.5) mice are shown. The Western blot analysis shows one representative blot of two analyses. Data are means ± SEM of the number of mice indicated. Each measurement was done in duplicate.
that in l-cycloserine–treated EAE mice, C16:0-Cer levels were significantly lower compared with vehicle-treated EAE mice. Moreover, l-cycloserine prevented the increase in mRNA and protein levels of iNOS and TNF-α in the lumbar spinal cord (Fig. 6C–F). These data indicate that C16:0-Cer mediates iNOS and TNF-α generation during the development of EAE (Fig. 7).

**Discussion**

It is known that sphingolipids play essential roles in the induction and progress of inflammation (28), but only few publications deal with the role of specific ceramides in the inflammatory process (29). For the first time, to our knowledge, we show that CerS6 and its product, C16:0-Cer, specifically contribute to the inflammatory process by inducing iNOS and TNF-α expression in the initial phase of EAE. This was implied by the following results: 1) In EAE mice in vivo, C16:0-Cer and CerS6 expression are increased in inflammatory cells such as migrated monocytes/macrophages and astroglia. Furthermore, l-cycloserine—an inhibitor of the de novo synthesis of ceramides—attenuated the clinical symptoms of EAE mice and prevented increases in C16:0-Cer as well as in iNOS and TNF-α. 2) In the cerebrospinal fluid of MS patients, C16:0-Cer was elevated 1.9-fold. 3) In IFN-γ–induced RAW 264.7 macrophages, C16:0-Cer is elevated in a time-dependent manner, and the increase in C16:0-Cer is not observed in CerS6–4 knockout RAW 264.7 macrophages. These data suggest that CerS6 and C16:0-Cer are involved in the development of EAE.

**FIGURE 6.** The serine palmitoyltransferase inhibitor l-cycloserine prevents, at least partially, the development of clinical symptoms in EAE mice and the increase in C16:0-Cer, iNOS, and TNF-α expression. (A) Clinical score of EAE mice that were treated daily with 75 mg/kg l-cycloserine or vehicle (saline) by i.p. injection. The EAE and CFA-treated mice were treated with l-cycloserine or vehicle (saline) when the EAE mice reached sc0.5. Data are means ± SEM of number of mice as indicated. The results were obtained from two different studies. (B) The ceramide levels of the l-cycloserine–treated or vehicle-treated EAE mice and CFA-treated mice were related to the ceramide levels of age-matched control mice. (C–F) The relative expression of iNOS mRNA (C), iNOS protein (D), TNF-α mRNA (E), and TNF-α protein (F) from l-cycloserine–treated and vehicle-treated EAE mice is shown. The mRNA expression levels were calculated using data of untreated age-matched control mice as baseline values. The Western blot analysis shows a representative blot of two determinations. Data are means ± SEM of number of mice as indicated. *p < 0.05 (significant difference between l-cycloserine–treated and saline-treated EAE mice). Cyclo, l-cycloserine.

**FIGURE 7.** The serine palmitoyltransferase inhibitor l-cycloserine prevents, at least partially, the development of clinical symptoms in EAE mice and the increase in C16:0-Cer, iNOS, and TNF-α expression. (A) Clinical score of EAE mice that were treated daily with 75 mg/kg l-cycloserine or vehicle (saline) by i.p. injection. The EAE and CFA-treated mice were treated with l-cycloserine or vehicle (saline) when the EAE mice reached sc0.5. Data are means ± SEM of number of mice as indicated. The results were obtained from two different studies. (B) The ceramide levels of the l-cycloserine–treated or vehicle-treated EAE mice and CFA-treated mice were related to the ceramide levels of age-matched control mice. (C–F) The relative expression of iNOS mRNA (C), iNOS protein (D), TNF-α mRNA (E), and TNF-α protein (F) from l-cycloserine–treated and vehicle-treated EAE mice is shown. The mRNA expression levels were calculated using data of untreated age-matched control mice as baseline values. The Western blot analysis shows a representative blot of two determinations. Data are means ± SEM of number of mice as indicated. *p < 0.05 (significant difference between l-cycloserine–treated and saline-treated EAE mice). Cyclo, l-cycloserine.

that in l-cycloserine–treated EAE mice, C16:0-Cer levels were significantly lower compared with vehicle-treated EAE mice. Moreover, l-cycloserine prevented the increase in mRNA and protein levels of iNOS and of TNF-α in the lumbar spinal cord (Fig. 6C–F). These data indicate that C16:0-Cer mediates iNOS and TNF-α generation during the development of EAE (Fig. 7).

Discussion

It is known that sphingolipids play essential roles in the induction and progress of inflammation (28), but only few publications deal with the role of specific ceramides in the inflammatory process (29). For the first time, to our knowledge, we show that CerS6 and its product, C16:0-Cer, specifically contribute to the inflammatory process by inducing iNOS and TNF-α expression in the initial phase of EAE. This was implied by the following results: 1) In EAE mice in vivo, C16:0-Cer and CerS6 expression are increased in inflammatory cells such as migrated monocytes/macrophages and astroglia. Furthermore, l-cycloserine—an inhibitor of the de novo synthesis of ceramides—attenuated the clinical symptoms of EAE mice and prevented increases in C16:0-Cer as well as in iNOS and TNF-α. 2) In the cerebrospinal fluid of MS patients, C16:0-Cer was elevated 1.9-fold. 3) In IFN-γ–induced RAW 264.7 macrophages, C16:0-Cer is elevated in a time-dependent manner, and the increase in C16:0-Cer is not observed in CerS6–4 knockout RAW 264.7 macrophages. These data suggest that CerS6 and C16:0-Cer are involved in the development of EAE.

**FIGURE 6.** The serine palmitoyltransferase inhibitor l-cycloserine prevents, at least partially, the development of clinical symptoms in EAE mice and the increase in C16:0-Cer, iNOS, and TNF-α expression. (A) Clinical score of EAE mice that were treated daily with 75 mg/kg l-cycloserine or vehicle (saline) by i.p. injection. The EAE and CFA-treated mice were treated with l-cycloserine or vehicle (saline) when the EAE mice reached sc0.5. Data are means ± SEM of number of mice as indicated. The results were obtained from two different studies. (B) The ceramide levels of the l-cycloserine–treated or vehicle-treated EAE mice and CFA-treated mice were related to the ceramide levels of age-matched control mice. (C–F) The relative expression of iNOS mRNA (C), iNOS protein (D), TNF-α mRNA (E), and TNF-α protein (F) from l-cycloserine–treated and vehicle-treated EAE mice is shown. The mRNA expression levels were calculated using data of untreated age-matched control mice as baseline values. The Western blot analysis shows a representative blot of two determinations. Data are means ± SEM of number of mice as indicated. *p < 0.05 (significant difference between l-cycloserine–treated and saline-treated EAE mice). Cyclo, l-cycloserine.

Discussion

It is known that sphingolipids play essential roles in the induction and progress of inflammation (28), but only few publications deal with the role of specific ceramides in the inflammatory process (29). For the first time, to our knowledge, we show that CerS6 and its product, C16:0-Cer, specifically contribute to the inflammatory process by inducing iNOS and TNF-α expression in the initial phase of EAE. This was implied by the following results: 1) In EAE mice in vivo, C16:0-Cer and CerS6 expression are increased in inflammatory cells such as migrated monocytes/macrophages and astroglia. Furthermore, l-cycloserine—an inhibitor of the de novo synthesis of ceramides—attenuated the clinical symptoms of EAE mice and prevented increases in C16:0-Cer as well as in iNOS and TNF-α. 2) In the cerebrospinal fluid of MS patients, C16:0-Cer was elevated 1.9-fold. 3) In IFN-γ–induced RAW 264.7 macrophages, C16:0-Cer is elevated in a time-dependent manner, and the increase in C16:0-Cer is not observed in CerS6–4 knockout RAW 264.7 macrophages. These data suggest that CerS6 and C16:0-Cer are involved in the development of EAE.

**FIGURE 6.** The serine palmitoyltransferase inhibitor l-cycloserine prevents, at least partially, the development of clinical symptoms in EAE mice and the increase in C16:0-Cer, iNOS, and TNF-α expression. (A) Clinical score of EAE mice that were treated daily with 75 mg/kg l-cycloserine or vehicle (saline) by i.p. injection. The EAE and CFA-treated mice were treated with l-cycloserine or vehicle (saline) when the EAE mice reached sc0.5. Data are means ± SEM of number of mice as indicated. The results were obtained from two different studies. (B) The ceramide levels of the l-cycloserine–treated or vehicle-treated EAE mice and CFA-treated mice were related to the ceramide levels of age-matched control mice. (C–F) The relative expression of iNOS mRNA (C), iNOS protein (D), TNF-α mRNA (E), and TNF-α protein (F) from l-cycloserine–treated and vehicle-treated EAE mice is shown. The mRNA expression levels were calculated using data of untreated age-matched control mice as baseline values. The Western blot analysis shows a representative blot of two determinations. Data are means ± SEM of number of mice as indicated. *p < 0.05 (significant difference between l-cycloserine–treated and saline-treated EAE mice). Cyclo, l-cycloserine.

Discussion

It is known that sphingolipids play essential roles in the induction and progress of inflammation (28), but only few publications deal with the role of specific ceramides in the inflammatory process (29). For the first time, to our knowledge, we show that CerS6 and its product, C16:0-Cer, specifically contribute to the inflammatory process by inducing iNOS and TNF-α expression in the initial phase of EAE. This was implied by the following results: 1) In EAE mice in vivo, C16:0-Cer and CerS6 expression are increased in inflammatory cells such as migrated monocytes/macrophages and astroglia. Furthermore, l-cycloserine—an inhibitor of the de novo synthesis of ceramides—attenuated the clinical symptoms of EAE mice and prevented increases in C16:0-Cer as well as in iNOS and TNF-α. 2) In the cerebrospinal fluid of MS patients, C16:0-Cer was elevated 1.9-fold. 3) In IFN-γ–induced RAW 264.7 macrophages, C16:0-Cer is elevated in a time-dependent manner, and the increase in C16:0-Cer is not observed in CerS6–4 knockout RAW 264.7 macrophages. These data suggest that CerS6 and C16:0-Cer are involved in the development of EAE.
phages and in peritoneal macrophages in vitro, the increase in C16:0-Cer/CerS6 was linked to iNOS/NO and TNF-α synthesis. Furthermore, downregulation of CerS6 prevented IFN-γ-induced iNOS expression and NO/TNF-α release, and an endogenous increase in C16:0-Cer amplified the IFN-γ-induced NO/TNF-α increase in RAW 264.7 macrophages. 4) EAE/IFN-γ KO mice revealed a delay in disease onset and a reduced induction of CerS6/C16:0-Cer, iNOS, and TNF-α expression compared with EAE/WT mice.

We also observed an increase in C16:0-Cer/CerS6 in the lumbar spinal cord of EAE mice. The increase could have been due to activation of CerS6 in macrophages or to the presence of a different cell population (migrated macrophages) in the lumbar spinal cord of EAE mice. The migrated cells possibly express more CerS6 in comparison to resident CNS cells. We suggest that the increase in C16:0-Cer/CerS6 level is due to activation of CerS6 in macrophages, because 1) CerS6 is expressed in macrophages in the lumbar spinal cord of EAE mice, 2) the increase in CerS6 in EAE mice is transient, whereas blood-derived macrophage numbers increase steadily in the spinal cord (22), and 3) the inhibition of CerS6 in primary macrophages prevents the IFN-γ-induced upregulation of iNOS and TNF-α.

The transient increase in C16:0-Cer/CerS6 at the beginning of the inflammatory process points toward a significant role of C16:0-Cer in the initial phase of MS. Furthermore, our results demonstrate for the first time, to our knowledge, a direct correlation between de novo synthesized C16:0-Cer and IFN-γ-induced NO and TNF-α synthesis (Fig. 7). Up to now, only ceramides synthesized by the salvage pathway or glycosylated ceramides have been reported to induce NO and TNF-α synthesis (30, 31). Innate or classical activation of macrophages by LPS or IFN-γ (32), respectively, induces sphingomyelinases (31) or de novo synthesis (as indicated by our results), respectively. Notably, in the initial phase of EAE, mainly Th1 cells that secrete IFN-γ are involved in the inflammatory process (33), suggesting an important role of de novo-synthesized ceramides in the initial phase of EAE.

Indeed, the induction of CerS6/C16:0-Cer was significantly reduced in EAE/IFN-γ KO mice compared with that in EAE/WT mice and was accompanied by a significant delay in disease onset in EAE/IFN-γ KO mice in comparison with EAE/WT mice. These results strengthen our hypothesis that IFN-γ-induced CerS6/C16:0-Cer play a critical role in the initial phase of the disease. However, EAE/IFN-γ KO mice, in comparison with EAE/WT mice treated with l-cycloserine, exhibited no disease amelioration; this might have been due to the dual anti-inflammatory and proinflammatory properties of the IFN-γ/NO/TNF-α pathway, as discussed below. The increase in C16:0-Cer in EAE/IFN-γ KO mice indicates that not only IFN-γ but also other stimuli regulate the C16:0-Cer level. We observed an increase in CerS6 in both macrophages and in astroglia. Kim et al. (34) showed that an increase in C16:0-Cer in astroglia correlates with oligodendrocyte apoptosis, which is a pathological hallmark of EAE contributing to disease worsening. The role of C16:0-Cer in other cell types will be the topic of further studies.

TNF-α and NO exert contradictory properties during the development of EAE/MS. A dual role for TNF-α was proposed: 1) TNF-α initiates a myelin-directed immune response (disease-stimulating effect) at the onset of the disease, and 2) later in the chronic phase it causes depletion of autoreactive lymphocytes and suppresses inflammation (disease-inhibiting effect). IFN-β and glatiramer acetate, both licensed for the treatment of relapsing–remitting MS, also reduce the TNF-α level in MS patients (35, 36). For NO, a similar dual role was suggested: 1) A high blood NO level before disease onset reduces T cell proliferation (disease-inhibiting effect) 2) while elevated NO level in the CNS at the onset of the disease acts as a tissue-damaging free radical (disease-stimulating effect). We showed that inhibition of C16:0-Cer synthesis at the onset of the disease reduces TNF-α and NO synthesis and abates disease progression. Unfortunately, specific inhibitors of C16:0-Cer synthesis or CerS6 KO mice are not available, as these would be helpful in confirming the relevance of C16:0-Cer in the development of EAE.

We postulate that C16:0-Cer acts as an inflammatory mediator. A prerequisite for mediators is sufficient mobility to reach potential target proteins. But ceramides are not water-soluble and therefore less mobile. This raises the question how ceramides could be transferred to their potential target proteins? It is known that ceramides can be transported by a specific transport protein CERT (37), by vesicles (38), and in neuronal cells by binding to cytoskeleton proteins (38). Furthermore, the occurrence of several ceramide synthases at different subcellular sites and therefore the formation of ceramides in different subcellular organelles might also overcome the immobility of ceramides (39). In the cerebrospinal fluid, C16:0-Cer is probably also bound to proteins. Albumin could be a carrier protein for ceramides as it binds hydrophobic substances, and ceramides have been reported to interact with the hydrophobic domains of proteins (40).

In conclusion, our data reveal that C16:0-Cer/CerS6 play a crucial role in the inflammatory process during the initial phase of EAE by regulating NO and TNF-α synthesis. Importantly, we also demonstrated that in the cerebrospinal fluid of MS patients, C16:0-Cer levels are upregulated, and Wheeler et al. (41) observed a slight increase in C16:0-Cer in the white matter of MS samples. Recently, Nikić et al. (42) showed that axonal damage induced by NO released from macrophages occurs in axons with intact myelin sheaths and that this process is reversible. These findings indicate that the early reduction in NO through inhibition of CerS6 may prevent axonal damage and subsequently prevent the development of MS (42). Therefore, CerS6 could be a promising target for the development of novel drugs to treat MS, and C16:0-Cer may be a potential novel biomarker in MS for diagnosis and treatment monitoring.

Acknowledgments

We thank Prof. Dr. Michael Parnham for the linguistic revision of the manuscript.

Disclosures

G.G., K.S., U.Z., and S.S. have a patent pending concerning the use of CerS6 as a target for the development of new MS drugs. The other authors have no financial conflicts of interest.

References


**Supplement 1:** The lumbar spinal cord was incubated with CerS6 antibody (red channel) and with cell marker antibodies (green channel) OSP (oligodendrocytes) (A), GFAP (astroglia) (B) or DR5 (apoptotic cells) (C). All data are representative images of three independent experiments. The magnification is 60x. Scale bar, 10 μm. **D)** RAW 264.7 macrophages were treated for 16h with 10 ng/ml IFN-γ, 5 ng/ml TNF-α or 1 ng/ml IL-1β. The ceramide levels were normalized to the number of treated cells. The relative increase of the specific ceramides was calculated using the ceramide levels of untreated cells as 100%. Data are mean ± s.e.m. of three independent experiments, each made in duplicate. * (p < 0.05), ** (p <0.01) indicate significant differences between cytokine-treated and untreated RAW 264.7 macrophages. **E)** RAW 264.7 macrophages were treated or nor for the time points indicated with 10 ng/ml IFN-γ. The relative mRNA expression of CerSs was calculated using the mRNA level of untreated cells at the same time point as basal level. Data are means ± s.e.m. of three independent experiments, each carried out in triplicate. * (p < 0.05), ** (p < 0.01), *** (p < 0.001) indicate significant differences between IFN-γ treated and untreated cells.
Supplement 2: A) RAW 264.7 were preincubated with 500 μM L-cycloserine (Cyclo) or 70 μM Fumonisin B1 (FB1) for 90 min or 30 min, respectively, and subsequently 10 ng/ml IFN-γ were added for 16h. The ceramide levels were related to the number of treated cells. The amount of ceramides in the control cells were set as 100%. Data are means ± s. e. m. of three comparable independent experiments. * p<0.05, ** p<0.01, *** p<0.001 indicate significant differences between IFN-γ treated cells and cells co-treated with IFN-γ and an inhibitor of the sphingolipid synthesis. B) The cell viability was determined with the WST proliferation assay (Roche Diagnostics). RAW 264.7 macrophages were co-treated with 10 ng/ml IFN-γ and Fumonisin B1 (70 μM) or L-cycloserine (500 μM) for 16h. The cell viability was determined by using IFN-γ treated cells as 100 %. Data are means ± s. e. m. of two comparable independent experiments. C) CerS5/CerS6 mRNA and ceramide levels (D) in scrambled (scr.) siRNA and siCerS6 treated RAW 264.7 macrophages, which were co-incubated with 10 ng/ml IFN-γ for 16 h. * (p < 0.05), *** (p < 0.001) indicate significant differences between siCerS6 treated and scrambled siRNA treated RAW 264.7 macrophages. E) RAW 264.7 macrophages were incubated with DMSO (control), 25 μM palmitic acid, 0.5 ng/ml IFN-γ or 25 μM palmitic acid and 0.5 ng/ml IFN-γ for 20 h. The ceramide levels were calculated using untreated cells at the same time point as the basal level. Data are means ± s. e. m. of two comparable independent experiments each done in duplicate. (ns; not significant)